Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited Fundamental Analysis
Neuren Pharmaceuticals Limited (NURPF) shows weak financial fundamentals with a PE ratio of 48.78, profit margin of 47.09%, and ROE of 9.20%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 69.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze NURPF's fundamental strength across five key dimensions:
Efficiency Score
WeakNURPF struggles to generate sufficient returns from assets.
Valuation Score
ModerateNURPF shows balanced valuation metrics.
Growth Score
ModerateNURPF shows steady but slowing expansion.
Financial Health Score
ExcellentNURPF maintains a strong and stable balance sheet.
Profitability Score
ModerateNURPF maintains healthy but balanced margins.
Key Financial Metrics
Is NURPF Expensive or Cheap?
P/E Ratio
NURPF trades at 48.78 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, NURPF's PEG of -0.43 indicates potential undervaluation.
Price to Book
The market values Neuren Pharmaceuticals Limited at 4.39 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 67.53 times EBITDA. This signals the market has high growth expectations.
How Well Does NURPF Make Money?
Net Profit Margin
For every $100 in sales, Neuren Pharmaceuticals Limited keeps $47.09 as profit after all expenses.
Operating Margin
Core operations generate 11.02 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.20 in profit for every $100 of shareholder equity.
ROA
Neuren Pharmaceuticals Limited generates $8.88 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Neuren Pharmaceuticals Limited generates strong operating cash flow of $125.42M, reflecting robust business health.
Free Cash Flow
Neuren Pharmaceuticals Limited generates strong free cash flow of $125.39M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.99 in free cash annually.
FCF Yield
NURPF converts 8.45% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
48.78
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
22.97
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
76.60
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How NURPF Stacks Against Its Sector Peers
| Metric | NURPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 48.78 | 27.86 | Worse (Expensive) |
| ROE | 9.20% | 763.00% | Weak |
| Net Margin | 47.09% | -20450.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.31 | Strong (Low Leverage) |
| Current Ratio | 76.60 | 4.50 | Strong Liquidity |
| ROA | 8.88% | -14743.00% (disorted) | Weak |
NURPF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Neuren Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation